The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivashchenko D.V.

Bekhterev St. Petersburg Psychoneurological Research Institute, St. Petersburg

Buromskaya N.I.

Sukhareva Research Practical Center of Children and Adolescents Mental Health, Moscow, Russia

Tazagulova M.Kh.

Russian Medical Academy for Continuing Professional Education, Moscow, Russia

Tutova A.D.

Sukhareva Research Practical Center of Children and Adolescents Mental Health, Moscow, Russia

Savchenko L.M.

Russian Medical Academy for Continuing Professional Education, Moscow, Russia

Shevchenko Iu.S.

Kafedra detskoĭ psikhiatrii i psikhoterapii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents

Authors:

Ivashchenko D.V., Buromskaya N.I., Tazagulova M.Kh., Tutova A.D., Savchenko L.M., Shevchenko Iu.S., Sychev D.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12): 132‑138

DOI: 10.17116/jnevro2019119121132

Read: 8489 times

Download PDF (RU)
Contact the author
Table of contents

EVIDENCE-BASED TREATMENT OF ACUTE PSYCHOTIC EPISODE AND SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS
EVIDENCE-BASED TREATMENT OF ACUTE PSYCHOTIC EPISODE AND SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS

To cite this article:

Ivashchenko DV, Buromskaya NI, Tazagulova MKh, Tutova AD, Savchenko LM, Shevchenko IuS, Sychev DA. Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(12):132‑138. (In Russ.)
https://doi.org/10.17116/jnevro2019119121132

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Effi­cacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79
Effe­ctiveness and tole­rability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):90-98
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Pharmacological pain mana­gement in pediatric inte­nsive care. Russian Journal of Pain. 2025;(1):56-61
Asse­ssment of the rela­tionship between the use of digi­tal devi­ces and the transformation of the daily routine of schoolchildren. Russian Journal of Preventive Medi­cine. 2025;(6):74-80
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Costs of home-based respiratory support and oxygen therapy. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):93-102
Resu­lts of manual therapy in dege­nerative spine diseases with and without radi­culopathy. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(4):47-55
Abstract:

Children and adolescents are a special group in the context of psychopharmacotherapy. Given the limited choice of registered antipsychotics permitted in childhood, caution should be exercised in the choice of medication. This literature review reviews the current evidence base for pharmacotherapy of acute psychotic episode and schizophrenia in children and adolescents. The results of major systematic reviews and meta-analyses are compared. Meta-analyses of pharmacotherapy studies of the first psychotic episode are considered separately. Antipsychotics of the first and second generation are comparable in effectiveness for children and adolescents with acute psychotic episode. Olanzapine demonstrates higher efficacy in reducing negative symptoms. Ziprasidone and asenapine are less effective in treating schizophrenia in children and adolescents than other antipsychotics. Compared to adults, children and adolescents are at higher risk of metabolic impairments when taking antipsychotics.

Keywords:

antipsychotics
acute psychotic episode
children and adolescents
early-onset schizophrenia
effectiveness

Authors:

Ivashchenko D.V.

Bekhterev St. Petersburg Psychoneurological Research Institute, St. Petersburg

Buromskaya N.I.

Sukhareva Research Practical Center of Children and Adolescents Mental Health, Moscow, Russia

Tazagulova M.Kh.

Russian Medical Academy for Continuing Professional Education, Moscow, Russia

Tutova A.D.

Sukhareva Research Practical Center of Children and Adolescents Mental Health, Moscow, Russia

Savchenko L.M.

Russian Medical Academy for Continuing Professional Education, Moscow, Russia

Shevchenko Iu.S.

Kafedra detskoĭ psikhiatrii i psikhoterapii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia, Moskva

Sychev D.A.

Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia

Close metadata

References:

  1. Newton R, Rouleau A, Nylander A-G, Loze J-Y, Resemann HK, Steeves S, Crespo-Facorro B. Diverse definitions of the early course of schizophrenia—a targeted literature review. NPJ Schizophrenia. 2018;4(1):21. https://doi.org/10.1038/s41537-018-0063-7
  2. Harvey RC, James AC, Shields GE. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016;30(1):27-39. https://doi.org/10.1007/s40263-015-0308-1
  3. Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am. 201;22(4):539-555. https://doi.org/10.1016/j.chc.2013.04.001
  4. Lachman A. New developments in diagnosis and treatment update: Schizophrenia/first episode psychosis in children and adolescents. J Child Adolesc Ment Health. 2014;26(2):109-124. https://doi.org/10.2989/17280583.2014.924416
  5. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1575-1586. https://doi.org/10.1016/S0140-6736(13)61611-6
  6. Remschmidt H, Theisen F. Early-onset schizophrenia. Neuropsychobiology. 2012;66(1):63-69. https://doi.org/10.1159/000338548
  7. Stafford MR, Mayo-Wilson E, Loucas CE, James A, Hollis C, Birchwood M, Kendall T. Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117166. https://doi.org/10.1371/journal.pone.0117166
  8. Jerrell JM, McIntyre RS. Factors Differentiating Childhood-Onset and Adolescent-Onset Schizophrenia:A Claims Database Study. Prim Care Companion CNS Disord. 2016;18(2). https://doi.org/10.4088/PCC.15m01901
  9. James A, Clacey J, Seagroatt V, Goldacre M. Adolescent inpatient psychiatric admission rates and subsequent one-year mortality in England: 1998—2004. J Child Psychol Psychiatry. 2010;51(12):1395-404. https://doi.org/10.1111/j.1469-7610.2010.02293.x
  10. Okkels N, Vernal DL, Jensen SO, McGrath JJ, Nielsen RE. Changes in the diagnosed incidence of early onset schizophrenia over four decades. Acta Psychiatr Scand. 2013;127(1):9-10. https://doi.org/10.1111/j.1600-0447.2012.01916.x
  11. Pletscher M, Mattli R, von Wyl A, Reich O, Wieser S. The Societal Costs of Schizophrenia in Switzerland. J Ment Health Policy Econ. 2015;18(2):93-103.
  12. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders. Curr Opin Psychiatry. 2013;26(2):219-230. https://doi.org/10.1097/YCO.0b013e32835dcc2a
  13. Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O’Day JA, Dardashti LJ, Warburton KD. «Meta-guidelines» for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150-162. https://doi.org/10.1017/S109285291300014X
  14. Díaz-Caneja CM, Pina-Camacho L, Rodríguez-Quiroga A, Fraguas D, Parellada M, Arango C. Predictors of outcome in early-onset psychosis: a systematic review. NPJ Schizophr. 2015;1:14005. https://doi.org/10.1038/npjschz.2014.5
  15. Heslin M, Lomas B, Lappin JM, Donoghue K, Reininghaus U, Onyejiaka A, Croudace T, Jones PB, Murray RM, Fearon P, Dazzan P, Morgan C, Doody GA. Diagnostic change 10 years after a first episode of psychosis. Psychol Med. 2015;45(13):2757-2769. https://doi.org/10.1017/S0033291715000720
  16. Remberk B, Bażyńska AK, Krempa-Kowalewska A, Rybakowski F. Adolescent insanity revisited: course and outcome in early-onset schizophrenia spectrum psychoses in an 8-year follow-up study. Compr Psychiatry. 2014;55(5):1174-1181. https://doi.org/10.1016/j.comppsych.2014.03.013
  17. Masi G, Liboni F. Management of Schizophrenia in Children and Adolescents. Drugs. 2011;71(2):179-208. https://doi.org/10.2165/11585350-000000000-00000
  18. Haddad PM, Correll CU. The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Ther Adv Psychopharmacol. 2018;8(11):303-318. https://doi.org/10.1177/2045125318781475
  19. Zhu Y, Li C, Huhn M, Rothe P, Krause M, Bighelli I, Schneider-Thoma J, Leucht S. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017;27(9):835-844. https://doi.org/10.1016/j.euroneuro.2017.06.011
  20. Jerrell JM, McIntyre RS, Deroche CB. Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia. Hum Psychopharmacol. 2017;32(2). https://doi.org/10.1002/hup.2585
  21. Abidi S. Psychosis in Children and Youth: Focus on Early-Onset Schizophrenia. Pediatr Rev. 2013;34(7):296-305; quiz 305-306. https://doi.org/10.1542/pir.34-7-296
  22. Winton-Brown TT, Elanjithara T, Power P, Coentre R, Blanco-Polaina P, McGuire P. Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis. Schizophr Res. 2017;179:50-56. https://doi.org/10.1016/j.schres.2016.09.029
  23. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071. https://doi.org/10.1016/S0140-6736(12)60239-6
  24. Wils RS, Gotfredsen DR, Hjorthøj C, Austin SF, Albert N, Secher RG, Thorup AA, Mors O, Nordentoft M. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res. 2017;182:42-48. https://doi.org/10.1016/j.schres.2016.10.030
  25. Revier CJ, Reininghaus U, Dutta R, Fearon P, Murray RM, Doody GA, Croudace T, Dazzan P, Heslin M, Onyejiaka A, Kravariti E, Lappin J, Lomas B, Kirkbride JB, Donoghue K, Morgan C, Jones PB. Ten-Year Outcomes of First-Episode Psychoses in the MRC ÆSOP-10 Study. J Nerv Ment Dis. 2015;203(5):379-386. https://doi.org/10.1097/NMD.0000000000000295
  26. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654-661.
  27. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2-3):408-414. https://doi.org/10.1016/j.schres.2013.08.001
  28. Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, Heslin M, Reininghaus UA, Donoghue K, Lomas B, Charalambides M, Onyejiaka A, Fearon P, Jones P, Doody G, Morgan C, Dazzan P, Murray RM. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-1989. https://doi.org/10.1017/S0033291717000435
  29. Conus P, Cotton SM, Francey SM, O’Donoghue B, Schimmelmann BG, McGorry PD, Lambert M. Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. Schizophr Res. 2017;185:130-136. https://doi.org/10.1016/j.schres.2016.12.029
  30. Bowtell M, Eaton S, Thien K, Bardell-Williams M, Downey L, Ratheesh A, Killackey E, McGorry P, O’Donoghue B. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res. 2018;195:231-236. https://doi.org/10.1016/j.schres.2017.10.030
  31. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. https://doi.org/10.1016/S0140-6736(08)60486-9
  32. Martinuzzi E, Barbosa S, Daoudlarian D, Bel Haj Ali W, Gilet C, Fillatre L, Khalfallah O, Troudet R, Jamain S, Fond G, Sommer I, Leucht S, Dazzan P, McGuire P, Arango C, Diaz-Caneja CM, Fleischhacker W, Rujescu D, Glenthøj B, Winter I, Kahn RS, Yolken R, Lewis S, Drake R, Davidovic L, Leboyer M, Glaichenhaus N; OPTiMiSE Study Group. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry. 2019;9(1):20. https://doi.org/10.1038/s41398-018-0366-5
  33. Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29(1):1-10. https://doi.org/10.1016/j.eurpsy.2013.08.001
  34. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodríguez-Sánchez JM, Pérez-Iglesias R, Vázquez-Barquero JL. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs. 2008;22(7):547-562.
  35. Foley DL, Morley KI. Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry. 2011;68(6):609-616. https://doi.org/10.1001/archgenpsychiatry.2011.2
  36. Calarge CA, Ivins SD, Motyl KJ, Shibli-Rahhal AA, Bliziotes MM, Schlechte JA. Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. Ther Adv Psychopharmacol. 2013;3(5):278-293. https://doi.org/10.1177/2045125313487548
  37. Pagsberg AK, Tarp S, Glintborg D, Stenstrøm AD, Fink-Jensen A, Correll CU, Christensen R. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(3):191-202. https://doi.org/10.1016/j.jaac.2016.12.013
  38. Lee ES, Vidal C, Findling RL. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. J Child Adolesc Psychopharmacol. 2018;28(9):582-605. https://doi.org/10.1089/cap.2018.0037
  39. Datta SS, Kumar A, Wright SD, Furtado VA, Russell PS. Evidence Base for Using Atypical Antipsychotics for Psychosis in Adolescents. Schizophr Bull. 2014;40(2):252-254. https://doi.org/10.1093/schbul/sbt196
  40. Armenteros JL, Davies M. Antipsychotics in early onset Schizophrenia. Eur Child Adolesc Psychiatry. 2006;15(3):141-148.
  41. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull. 2010;43(2):45-66.
  42. Xia L, Li WZ, Liu HZ, Hao R, Zhang XY. Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials. J Child Adolesc Psychopharmacol. 2018;28(4):244-251. https://doi.org/10.1089/cap.2017.0120
  43. Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, Leucht S. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659-674. https://doi.org/10.1016/j.euroneuro.2018.03.008
  44. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205-1218. https://doi.org/10.1017/S1461145712001277
  45. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457. https://doi.org/10.1093/schbul/sbn018
  46. Galling B, Roldán A, Hagi K, Rietschel L, Walyzada F, Zheng W, Cao XL, Xiang YT, Zink M, Kane JM, Nielsen J, Leucht S, Correll CU. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77-89. https://doi.org/10.1002/wps.20387
  47. Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand. 2018;137(3):187-205. https://doi.org/10.1111/acps.12854
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.